Athira Pharma stock nosedives after Alzheimer’s drug trial results disappoint
Athira Pharma's stock plunged by 75% after the company announced that its Phase 2/3 LIFT-AD clinical trial for its experimental Alzheimer’s drug, fosgonimeton, failed to ... Read More
Amylyx Pharmaceuticals’ AMX0035 misses primary and secondary endpoints in ALS study
Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the pharmaceutical industry, announced today the top-line results of the PHOENIX study, a critical ... Read More
Nura Bio kicks off Phase 1 clinical trials for SARM1 inhibitor NB-4746
Nura Bio, a leading biopharmaceutical company specializing in neuroprotective, small molecule therapies, announced today the initiation of Phase 1 clinical trials for its groundbreaking SARM1 ... Read More
Amylyx Pharmaceuticals gets RELYVRIO FDA approval for ALS
RELYVRIO FDA approval for ALS : Amylyx Pharmaceuticals has secured approval for RELYVRIO (sodium phenylbutyrate and taurursodiol) from the US Food and Drug Administration (FDA) ... Read More
BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS
NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the ... Read More
Yumanity secures $500m worth deal with Merck to develop therapies for neurodegenerative disorders
Massachusetts-based Yumanity Therapeutics has secured a drug development deal worth up to nearly $500 million with pharma giant Merck to develop new therapies for neurodegenerative ... Read More
Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS
Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS (ravulizumab) for the treatment of amyotrophic lateral ... Read More
CMD enrolls first patient in placebo-controlled ALS trial of CuATSM
Collaborative Medicinal Development (CMD) has enrolled the first patient in a placebo-controlled clinical trial to evaluate the safety and efficacy of CuATSM in patients with ... Read More